The global Epidermolysis Bullosa market is estimated to be valued at US$ 3,429.30 Mn in 2024 and is expected to exhibit a CAGR of 11.% over the forecast period 2023 to 2030. Epidermolysis bullosa (EB) is a group of rare inherited disorders that affect the skin and in some types an internal mucosal epithelia. The epidermis separates from the dermis resulting from minor injury or friction leaving open painful blisters or wounds. Treatment includes preventing/managing infections and wounds, pain relief, nutritional support and reconstructive surgery in severe forms.
Key Takeaways
Key players operating in the Epidermolysis Bullosa market are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair. Amryt Pharma\'s Oleogel-S10 is currently under review with the FDA for treating EB. Increasing research on gene therapy and expanding treatment options like autologous keratinocyte transplantation are fueling market growth. Technological advancements like development of artificial skin by Phoenix Tissue Repair having properties similar to human skin for temporary wound coverage are allowing improved treatment of EB.
Market Trends
The increasing research on gene therapy is a key trend in EB market. Vendors are developing gene therapies to replace mutated genes, stop skin from blistering and healing wounds. Another key trend is launch of new drugs for EB treatment. In 2021, Abeona Therapeutics received rare pediatric disease designation from FDA for ABO-102 for EB treatment. The therapy uses AAV-based gene transfer to deliver COL7A1 gene involved in EB.
Market Opportunities
Rising awareness through organizations like DEBRA International and funding for research presents an opportunity. Developing countries also represent significant potential due to growing healthcare infrastructure. Technological developments in creating artificial skin grafts and stem cell therapy can boost the market by providing permanent relief to patients.
Impact of COVID-19 on Epidermolysis Bullosa Market Growth
The COVID-19 pandemic has significantly impacted the growth of the epidermolysis bullosa market. During the initial phase of the pandemic, supply chain disruption and resource reallocation towards the treatment of COVID-19 patients negatively affected the market. However, as the pandemic progressed, several initiatives were taken by governments as well as private organizations to support epidermolysis bullosa patients. Telemedicine platforms were widely adopted to enable remote consultations and ensure continuity of care. Research activities also gained momentum as manufacturers collaborated to fast-track the development of novel therapies. Though the clinical trials were delayed initially, regulatory agencies provided flexibility to acceleratethe review and approval process. As the pandemic is now gradually being brought under control with mass vaccination drives, the epidermolysis bullosa market is anticipated to rebound and witness steady growth over the forecast period supported by the aforementioned measures and increasing awareness about the condition.
North America is the largest market for Epidermolysis Bullosa
North America dominates the global epidermolysis bullosa market in terms of value owing to the high prevalence of the condition, advanced healthcare infrastructure, availability of specialty centers to diagnose and treat rare diseases, and presence of prominent players. The region accounted for around 40% share of the overall market revenue in 2024. Additionally, favorable reimbursement policies and growing adoption of gene and cell therapies further support the growth of the epidermolysis bullosa market in North America. Rising awareness through patient support organizations also plays a key role. With continuous product approvals and ongoing clinical trials, North America is expected to retain its leading position over the next few years.
Asia Pacific represents the fastest growing region for Epidermolysis Bullosa Market
Asia Pacific region is poised to register the fastest growth in the global epidermolysis bullosa market during the forecast period attributed to increasing healthcare spending, large untapped patient pool, and improving accessibility of advanced treatment options. Emerging countries like India, China, and South Korea are the major revenue contributors to the Asia Pacific market. Further, favorable government policies for rare disease treatment combined with growing medical tourism are supporting the growth of epidermolysis bullosa market in Asia Pacific. Moreover, as regional players are investing in R&D activities, a rise in new product launches will also accelerate the market growth.
Sign in to leave a comment.